A
Annexon, Inc. (ANNX)
NMS – Real Time Price. Currency in USD
5.44
-0.24 (-4.23%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
5.44
-0.24 (-4.23%)
At close: May 12, 2026, 4:00 PM EDT
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
| Name | Position |
|---|---|
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP |
| Dr. Jamie Dananberg M.D. | Executive VP & Chief Medical Officer |
| Dr. Lloyd Clark M.D. | Senior Vice President of Ophthalmology Strategy & Innovation |
| Dr. Sunil Mehta Pharm.D. | Senior VP of Medical Affairs |
| Dr. Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board |
| Mr. Douglas E. Love Esq., J.D. | CEO, President & Director |
| Mr. Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine |
| Mr. Michael Overdorf M.B.A. | Executive VP & Chief Business Officer |
| Mr. Shikhar Agarwal M.B.A. | Senior VP & Head of Commercial |
| Ms. Jennifer Lew CPA | Executive VP, CFO & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 10-Q | annx-20260331.htm |
| 2026-04-27 | DEFA14A | ny20063060x3_defa14a.htm |
| 2026-04-16 | PRE 14A | ny20063060x1_pre14a.htm |
| 2026-03-31 | S-8 | d25477ds8.htm |
| 2026-03-30 | 8-K | annx-20260330.htm |
| 2026-03-30 | 10-K | annx-20251231.htm |
| 2026-02-17 | 8-K | d21497d8k.htm |
| 2026-01-14 | 8-K | d31215d8k.htm |
| 2026-01-12 | 8-K | d75965d8k.htm |
| 2025-11-14 | 8-K | d874883d8k.htm |